| dbo:abstract |
Volanesorsen, sold under the brand name Waylivra, is a triglyceride-reducing drug. It is a second-generation 2'-O-methoxyethyl (2'-MOE) chimeric antisense therapeutic oligonucleotide (ASO) that targets the messenger RNA for apolipoprotein C3 (apo-CIII). The most common side effects include reduced platelet levels and reactions at the site of the injection such as pain, swelling, itching, or bruising. Volanesorsen, is an 'antisense oligonucleotide,' a very short piece of synthetic RNA (a type of genetic material). It has been designed to block the production of a protein that slows down the breakdown of fats called apolipoprotein C-III. By blocking the production of this protein, the medicine reduces the level of triglycerides in the blood and, as a result, fat accumulation in the body, which is expected to reduce the risk of pancreatitis. (en) |
| dbo:alternativeName |
Waylivra (en) |
| dbo:casNumber |
(sodiumsalt) 915430-78-3 |
| dbo:chEMBL |
3544994 |
| dbo:drugbank |
DB15067 |
| dbo:fdaUniiCode |
2O4BE0K238 |
| dbo:kegg |
D11648 D11650 |
| dbo:pubchem |
122409770 |
| dbo:thumbnail |
wiki-commons:Special:FilePath/Volanesorsen.svg?width=300 |
| dbo:wikiPageExternalLink |
https://druginfo.nlm.nih.gov/drugportal/name/volanesorsen |
| dbo:wikiPageID |
52661206 (xsd:integer) |
| dbo:wikiPageLength |
14128 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID |
1090380996 (xsd:integer) |
| dbo:wikiPageWikiLink |
dbr:Messenger_RNA dbc:Therapeutic_gene_modulation dbr:Antisense_therapy dbr:International_nonproprietary_name dbr:Oligonucleotide dbr:Orphan_drug dbr:Apolipoprotein_C3 dbr:Subcutaneous_injection dbr:Familial_chylomicronemia_syndrome dbc:Orphan_drugs dbr:European_Medicines_Agency dbr:Familial_partial_lipodystrophy dbc:Hypolipidemic_agents dbr:Ionis_Pharmaceuticals dbc:Antisense_RNA dbr:Sodium dbr:Hypolipidemic_agent dbr:Hypertriglycidemia dbr:File:Volanesorsen.svg |
| dbp:atcPrefix |
10.0 |
| dbp:atcSuffix |
AX18 (en) |
| dbp:c |
230 (xsd:integer) |
| dbp:casNumber |
915430 (xsd:integer) |
| dbp:chembl |
3544994 (xsd:integer) |
| dbp:chemspiderid |
34982934 (xsd:integer) |
| dbp:drugbank |
DB15067 (en) |
| dbp:h |
320 (xsd:integer) |
| dbp:iupacName |
all-P-ambo-2'-O--P-thioadenylyl--2'-O--P-thioguanylyl--2'-O--5-methyl-P-thiocytidylyl--2'-O--5-methyl-P-thiouridylyl--2'-O--5-methyl-P-thiouridylyl--2'-deoxy-5-methyl-P-thiocytidylyl--P-thiothymidylyl--P- thiothymidylyl--2'-deoxy-P-thioguanylyl--P-thiothymidylyl--2'-deoxy-5-methyl-P-thiocytidylyl--2'-deoxy-5-methyl-P-thiocytidylyl--2'-deoxy-P-thioadenylyl--2'-deoxy-P-thioguanylyl--2'-deoxy-5-methyl-P-thiocytidylyl--2'-O--5-methyl-P-thiouridylyl--2'-O--5-methyl-P-thiouridylyl--2'-O--5-methyl-P-thiouridylyl--2'-O--P-thioadenylyl--2'-O--5-methyluridine (en) |
| dbp:jmol |
none (en) |
| dbp:kegg |
D11648 (en) D11650 (en) |
| dbp:legalEu |
Rx-only (en) |
| dbp:legalStatus |
Rx-only (en) |
| dbp:legalUk |
POM (en) |
| dbp:n |
63 (xsd:integer) |
| dbp:o |
125 (xsd:integer) |
| dbp:p |
19 (xsd:integer) |
| dbp:pubchem |
122409770 (xsd:integer) |
| dbp:routesOfAdministration |
dbr:Subcutaneous_injection |
| dbp:s |
19 (xsd:integer) |
| dbp:smiles |
Cc1cn[C@H]2C[C@@H]OPS (en) |
| dbp:stdinchi |
1 (xsd:integer) |
| dbp:stdinchikey |
IJUQCWMZCMFFJP-GQSLRNSLSA-N (en) |
| dbp:synonyms |
ISIS 304801, ISIS-APOCIIIRx (en) |
| dbp:tradename |
Waylivra (en) |
| dbp:unii |
2 (xsd:integer) |
| dbp:wikiPageUsesTemplate |
dbt:CAS dbt:Cite_web dbt:Drugbox dbt:Portal_bar dbt:Reflist dbt:Rp dbt:When dbt:Lipid_modifying_agents |
| dcterms:subject |
dbc:Therapeutic_gene_modulation dbc:Orphan_drugs dbc:Hypolipidemic_agents dbc:Antisense_RNA |
| rdf:type |
owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug |
| rdfs:comment |
Volanesorsen, sold under the brand name Waylivra, is a triglyceride-reducing drug. It is a second-generation 2'-O-methoxyethyl (2'-MOE) chimeric antisense therapeutic oligonucleotide (ASO) that targets the messenger RNA for apolipoprotein C3 (apo-CIII). The most common side effects include reduced platelet levels and reactions at the site of the injection such as pain, swelling, itching, or bruising. (en) |
| rdfs:label |
Volanesorsen (en) |
| owl:sameAs |
yago-res:Volanesorsen wikidata:Volanesorsen dbpedia-fa:Volanesorsen dbpedia-vi:Volanesorsen https://global.dbpedia.org/id/2YPUD |
| prov:wasDerivedFrom |
wikipedia-en:Volanesorsen?oldid=1090380996&ns=0 |
| foaf:depiction |
wiki-commons:Special:FilePath/Volanesorsen.svg |
| foaf:isPrimaryTopicOf |
wikipedia-en:Volanesorsen |
| is dbo:product of |
dbr:Ionis_Pharmaceuticals |
| is dbo:wikiPageRedirects of |
dbr:Volanesorsen_sodium dbr:Waylivra |
| is dbo:wikiPageWikiLink of |
dbr:Antisense_therapy dbr:Lipodystrophy dbr:Ionis_Pharmaceuticals dbr:ATC_code_C10 dbr:Volanesorsen_sodium dbr:Waylivra |
| is dbp:products of |
dbr:Ionis_Pharmaceuticals |
| is foaf:primaryTopic of |
wikipedia-en:Volanesorsen |
